title: Left ventricular myofilament dysfunction in rat experimental hypertrophy and congestive heart failure.
abstract: It is currently unclear whether left ventricular (LV) myofilament function is depressed in experimental LV hypertrophy (LVH) or congestive heart failure (CHF). To address this issue, we studied pressure overload-induced LV hypertrophy (POLVH) and myocardial infarction-elicited congestive heart failure (MICHF) in rats. LV myocytes were isolated from control, POLVH, and MICHF hearts by mechanical homogenization, skinned with Triton, and attached to micropipettes that projected from a sensitive force transducer and high-speed motor. A subset of cells was treated with either unphosphorylated, recombinant cardiac troponin (cTn) or cTn purified from either control or failing ventricles. LV myofilament function was characterized by the force-[Ca(2+)] relation yielding Ca(2+)-saturated maximal force (F(max)), myofilament Ca(2+) sensitivity (EC(50)), and cooperativity (Hill coefficient, n(H)) parameters. POLVH was associated with a 35% reduction in F(max) and 36% increase in EC(50). Similarly, MICHF resulted in a 42% reduction in F(max) and a 30% increase in EC(50). Incorporation of recombinant cTn or purified control cTn into failing cells restored myofilament Ca(2+) sensitivity toward levels observed in control cells. In contrast, integration of cTn purified from failing ventricles into control myocytes increased EC(50) to levels observed in failing myocytes. The F(max) parameter was not markedly affected by troponin exchange. cTnI phosphorylation was increased in both POLVH and MICHF left ventricles. We conclude that depressed myofilament Ca(2+) sensitivity in experimental LVH and CHF is due, in part, to a decreased functional role of cTn that likely involves augmented phosphorylation of cTnI.
authors.affiliation: Dept. of Physiology & Biophysics, Univ. of Illinois at Chicago, 835 S. Wolcott (M/C 901 Chicago, IL 60612, USA.
authors.forename: Rashad J
authors.initials: RJ
authors.lastname: Belin
authors.forename: Marius P
authors.initials: MP
authors.lastname: Sumandea
authors.forename: Tomoyoshi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Lori A
authors.initials: LA
authors.lastname: Walker
authors.forename: Veronica L
authors.initials: VL
authors.lastname: Rundell
authors.forename: Dalia
authors.initials: D
authors.lastname: Urboniene
authors.forename: Milana
authors.initials: M
authors.lastname: Yuzhakova
authors.forename: Stuart H
authors.initials: SH
authors.lastname: Ruch
authors.forename: David L
authors.initials: DL
authors.lastname: Geenen
authors.forename: R John
authors.initials: RJ
authors.lastname: Solaro
authors.forename: Pieter P
authors.initials: PP
authors.lastname: de Tombe
mesh_terms: D008841:Actin Cytoskeleton / Q000502:physiology*; D000818:Animals; D005260:Female; D006333:Heart Failure / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000473:pathology / Q000503:physiopathology*; D066298:In Vitro Techniques; D007525:Isoelectric Focusing; D009203:Myocardial Infarction / Q000209:etiology / Q000473:pathology; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000502:physiology; D010766:Phosphorylation / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D019209:Troponin C / Q000235:genetics / Q000494:pharmacology; D018487:Ventricular Dysfunction, Left / Q000209:etiology / Q000473:pathology / Q000503:physiopathology*
chemical_list: D011994:Recombinant Proteins; D019209:Troponin C